Somatic mutations in TBX3 promote hepatic clonal expansion by accelerating VLDL secretion
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci191855 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Gregory Mannino und 15 weiteren Autor:innen. Beteiligte Einrichtung: Children's Research Institute, Department of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, Simmons Comprehensive Ca…. Hauptthemen laut MEDLINE: T-Box Domain Proteins, Lipoproteins, VLDL, Liver, Fatty Liver. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIDDK NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Somatic mutations that increase clone fitness or resist disease are positively selected, but the impact of these mutations on organismal health remains unclear. We previously showed that Tbx3 deletion increases hepatocyte fitness within fatty livers. Here, we detected TBX3 somatic mutations in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). In mice, Tbx3 deletion protected against, whereas Tbx3 overexpression exacerbated, MASLD. Tbx3 deletion reduced lipid overload by accelerating VLDL secretion. Choline-deficient diets, which block VLDL secretion, abrogated this protective effect. TBX3 transcriptionally suppressed the conventional secretory pathway and cholesterol biosynthesis. Hdlbp is a direct target of TBX3 that is responsible for the altered VLDL secretion. In contrast to wild-type TBX3 , the TBX3 I155S and A280S mutations found in patients failed to suppress VLDL secretion. In conclusion, TBX3 mutant clones expand during MASLD through increased lipid disposal, demonstrating that clonal fitness can benefit the liver at the cost of hyperlipidemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Research Institute, Department of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, Simmons Comprehensive Cancer Center, Children's Research Institute Mouse Genome Engineering Co…
- Department of Immunology; and.
- Department of Pathology; University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Cancer Genome Project, Wellcome Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
- Quotient Therapeutics, Little Chesterford, Saffron Walden, United Kingdom.
- University of Cambridge Department of Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Förderung
- NIAID NIH HHS
- NIDDK NIH HHS
- NCI NIH HHS
Zitieren
APA
Mannino, G., Quinn, G., Zhu, M., Wang, Z., Wang, X., Li, B., Hsieh, M. H., Mathews, T., Zacharias, L., Gu, W., Gopal, P., Brzozowska, N., Campbell, P., Hoare, M., Liszczak, G., & Zhu, H. (2025). Somatic mutations in TBX3 promote hepatic clonal expansion by accelerating VLDL secretion. Journal of Clinical Investigation. https://doi.org/10.1172/jci191855
Vancouver
Mannino G, Quinn G, Zhu M, Wang Z, Wang X, Li B, et al. Somatic mutations in TBX3 promote hepatic clonal expansion by accelerating VLDL secretion. Journal of Clinical Investigation. 2025. doi:10.1172/jci191855
BibTeX
@article{Mannino2025,
author = {Mannino, Gregory and Quinn, Gabriella and Zhu, Min and Wang, Zixi and Wang, Xun and Li, Boyuan and Hsieh, Meng-Hsiung and Mathews, Thomas and Zacharias, Lauren and Gu, Wen and Gopal, Purva and Brzozowska, Natalia and Campbell, Peter and Hoare, Matt and Liszczak, Glen and Zhu, Hao},
title = {Somatic mutations in TBX3 promote hepatic clonal expansion by accelerating VLDL secretion},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci191855}
}
EUVIMED